Paradigm Reaches Milestone, Triggers Payment in Monsanto Agbio Deal | GenomeWeb

NEW YORK, Sept. 26 - Paradigm Genetics has met a fifth milestone in an agricultural gene-discovery partnership with Monsanto Company, triggering an undisclosed accelerated milestone payment, the functional genomics company said on Wednesday.

Paradigm also announced that Monsanto has amended the partnership by removing its termination option in exchange for broader rights. “This amendment is significant since it commits Monsanto to a total term of at least six years, with options to extend the scope of work in time and volume,” Paradigm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.